Synthetic Biologics will host a conference call and webcast to

ROCKVILLE, Md., March 10, 2022 (GLOBE NEWSWIRE) — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapies designed to address diseases in areas of high unmet need, announced today that it plans to host a conference call on Wednesday, March 16, 2022 at 4:30 p.m. ET to discuss its financial results for the fiscal year ended December 31, 2021 and provide a business update .

Individuals may participate in the live call by telephone by dialing (877) 451-6152 (domestic) or (201) 389-0879 (international) and using conference ID: 13727535. Participants are requested to dial the number 15 minutes before the start of the call to register. Investors and the public can access the live and archived webcast of this call via the “News & Media” section of the Company’s website, https://www.syntheticbiologics.com, under “Events” or by clicking here , for 90 days after the appeal.

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE American: SYN) is a diversified clinical-stage company that develops therapeutic products designed to treat diseases in areas of high unmet need. The Company recently announced that it has entered into a definitive agreement to acquire VCN Biosciences, SL (VCN), which is developing a novel oncolytic adenovirus (OV) platform designed for intravenous (IV) and intravitreal administration to trigger tumor cell death , improve the access of co-administered cancer therapies to the tumor and promote a robust anti-tumor response supported by the patient’s immune system. In addition, the Company’s lead candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade certain IV beta-lactam antibiotics commonly used in the gastrointestinal (GI) tract to prevent (a) damage to the microbiome, (b) Clostridioides difficile (CDI), (c) overgrowth of pathogenic organisms, (d) emergence of antimicrobial resistance (AMR), and (e) acute graft versus host disease (aGVHD ) in allogeneic hematopoietic cell (HCT) transplant recipients, and (2) SYN-020, a recombinant oral formulation of the intestinal alkaline phosphatase (IAP) enzyme produced under cGMP conditions and intended to treat both diseases local gastrointestinal and systemic diseases. For more information, please visit the Synthetic Biologics website at www.syntheticbiologics.com.

For more information, please contact:

Investor Relations:
Chris Calabrian
LifeSci Advisors, LLC
[email protected]
+1-917-680-5608

Michael P. Boser